Inconsistency of Reported Uremic Toxin Concentrations
- 15 June 2007
- journal article
- review article
- Published by Wiley in Artificial Organs
- Vol. 31 (8) , 600-611
Abstract
Abstract: Discrepancies in reported uremic toxin concentrations were evaluated for 78 retention solutes. For this analysis, 378 publications were screened. Up to eight publications per toxin were retained. The highest and the lowest reported concentrations, as well as the median reported concentration were registered. The ratio between the highest and the lowest (H/L) concentrations and, for some solutes, also the ratio between the highest and the median (H/M) concentrations were calculated. The compounds were arbitrarily subdivided into three groups based on their H/L ratio: group A, H/L < 3 (n = 33); group B, 3 < H/L < 8.5 (n = 20); and group C, H/L > 8.5 (n = 25). Solutes of groups A and B showed a low to intermediate scatter, suggesting a homogeneity of reported data. Group C showed a more substantial scatter. For at least 10 compounds of group C, extremely divergent concentrations were registered (H/M > 5.5) using scatter plot analysis. For all solutes of groups A and B, the highest reported concentration could be used as a reference. For some solutes of group C and for the compounds showing a divergent scatter analysis, however, more refined directives should be followed.Keywords
This publication has 133 references indexed in Scilit:
- Review on uremic toxins: Classification, concentration, and interindividual variabilityKidney International, 2003
- Homocysteine and lipid peroxidation in haemodialysis: role of folinic acid and vitamin ENephrology Dialysis Transplantation, 2001
- Lowering plasma levels of complement factor D with AN69 dialysis membranesJournal of Clinical Apheresis, 1999
- Increase in Three α,β-Dicarbonyl Compound Levels in Human Uremic Plasma: Specificin VivoDetermination of Intermediates in Advanced Maillard ReactionBiochemical and Biophysical Research Communications, 1999
- Hemodialysis Hypotension: Interaction of Inhibitors, iNOS, and the Interdialytic PeriodThe American Journal of the Medical Sciences, 1999
- Immunologic function and survival in hemodialysis patientsKidney International, 1998
- Vasoactive hormones in uraemic patients with chronic hypotensionNephrology Dialysis Transplantation, 1997
- Advanced oxidation protein products as a novel marker of oxidative stress in uremiaKidney International, 1996
- Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control studyAtherosclerosis, 1995
- Serum Melatonin and 6‐Sulfatoxymelatonin in End‐Stage Renal Disease: Effect of HemodialysisArtificial Organs, 1993